Keyora Antarctic Krill Oil EP-13: The Tear-Film Homeostasis and Ocular-Surface Response Matrix: From MGD, Hyperosmolarity, and Inflammation to Screen-Related Dry Eye and Phenotype-Matched Phospholipid Omega-3 Response

Background Dry Eye Disease is frequently described as a disorder of insufficient tears. Contemporary ocular-surface science supports a broader model. DED is a multifactorial disease characterized by loss of tear-film and/or ocular-surface homeostasis in which tear instability, excessive evaporation, hyperosmolar stress, inflammatory amplification, epithelial damage, altered sensory processing, eyelid or meibomian-gland dysfunction, and reduced aqueous contribution can operate individually or in combination. This heterogeneity creates a fundamental intervention problem. Patients can share the same diagnosis while possessing different dominant biological bottlenecks. One patient may have an evaporation-dominant phenotype. Another may have primarily aqueous-deficient disease. A third may have meibomian-gland dysfunction with lipid-deficient tear-film instability. Another may exhibit mixed disease with hyperosmolar inflammatory amplification. Screen exposure can generate a distinct environment in which reduced blink frequency, incomplete blinking, prolonged ocular-surface exposure, and evaporation become prominent upstream drivers. Symptoms can also diverge from objective signs because tear-film abnormalities, ocular-surface damage, gland dysfunction, and neurosensory processing do not necessarily change in parallel. These differences mean that Dry Eye Disease cannot be treated as one intervention object or one response object. Keyora Antarctic Krill Oil EP-13 develops Keyora [The Tear-Film Homeostasis and Ocular-Surface Response Matrix] as the central biological framework for reconstructing this complexity. It links: etiological driver → dominant homeostasis failure → tear-film consequence → ocular-surface stress → measurable response object. The article then applies Keyora [The Dry-Eye Phenotype Matching Rule], Keyora [The Dry-Eye Evidence Object Map], Keyora [The Dry-Eye Symptom-Sign Separation Rule], Keyora [The MGD Response Object Map], Keyora [The MGD Phenotype Fit Rule], Keyora [The Oral-Systemic vs Local-Gland Separation Rule], and Keyora [The Ocular-Surface Inflammatory Response Model] before integrating the full evidence architecture into Keyora [The Dry-Eye Phenotype Matching and Response Algorithm]. The controlling Keyora intervention identity is Phospholipid Omega-3. EPA and DHA are interpreted within a phospholipid-associated systemic nutritional architecture rather than as generic Omega-3 exposure. PC and broader phospholipids remain part of the formulation and structural-delivery context. Choline remains a secondary nutritional contribution. DPA remains visible as a declared long-chain n-3 component without being promoted into an independent dry-eye efficacy claim. The intervention is systemic. It does not act as artificial tears, does not directly lubricate the ocular surface, does not physically replace meibum, and does not directly restore lacrimal aqueous secretion. Its relevance depends upon whether systemic fatty-acid exposure, membrane lipid biology, and lipid-mediator pathways correspond to the dominant dry-eye phenotype and whether that response can be demonstrated through an endpoint appropriate to the biological task. Objective The objectives of EP-13 are to: establish Dry Eye Disease as a disorder of tear-film and ocular-surface homeostasis rather than a one-dimensional tear-deficiency state; distinguish aqueous deficiency, excessive evaporation, lipid-related instability, mixed disease, inflammatory amplification, neurosensory involvement, and environmental drivers; define Keyora [The Tear-Film Homeostasis and Ocular-Surface Response Matrix] as the article-level biological master framework; distinguish tear quantity from tear stability; distinguish TBUT and NIBUT from Schirmer testing; distinguish symptoms, tear stability, tear quantity, tear osmolarity, ocular-surface integrity, inflammatory biomarkers, and gland findings as different response objects; establish Keyora [The Dry-Eye Evidence Object Map]; establish Keyora [The Dry-Eye Symptom-Sign Separation Rule]; establish Keyora [The Dry-Eye Phenotype Matching Rule] so that intervention selection follows the dominant homeostasis failure rather than the diagnosis alone; distinguish systemic oral Phospholipid Omega-3 intervention from topical tear replacement; reject the interpretation that oral phospholipids physically reconstruct the tear-film lipid layer; reject the interpretation that oral PC directly substitutes for meibomian secretion; position EPA and DHA within systemic membrane and lipid-mediator biology relevant to selected DED phenotypes; preserve phospholipid-form identity during evidence interpretation without asserting universal superiority over TG, rTG, or EE Omega-3; define MGD as an important but non-universal evaporative dry-eye phenotype; distinguish meibomian-gland abnormality from actual functional lipid-deficient tear-film failure; establish Keyora [The MGD Response Object Map]; establish Keyora [The MGD Phenotype Fit Rule]; separate oral systemic lipid intervention from local gland management through Keyora [The Oral-Systemic vs Local-Gland Separation Rule]; reconcile positive and null MGD Omega-3 trials without collapsing different formulations and endpoints; establish hyperosmolarity as an amplification gate connecting upstream instability or inadequate replenishment with epithelial stress; integrate innate inflammatory activation, adaptive immune participation, and Th17 / IL-17-related biology into the ocular-surface inflammatory phenotype; position EPA/DHA lipid-mediator biology as a plausible systemic interface without converting mechanism into clinical efficacy; establish Keyora [The Ocular-Surface Inflammatory Response Model]; evaluate the direct randomized human Krill Oil DED trial endpoint by endpoint; distinguish favorable Krill Oil effects in tear osmolarity, OSDI symptoms, selected tear-stability measures, and tear IL-17A from null or nonuniform outcomes in other measured domains; prevent direct Krill Oil evidence from being interpreted as universal Krill Oil efficacy; prevent intervention-class Krill Oil evidence from being relabeled as exact finished-Keyora efficacy; integrate the major DREAM null trial as an important boundary against universal Omega-3 DED claims; reconcile conservative and broader meta-analytic findings by preserving differences in population, formulation, phenotype, comparator, duration, and endpoint; recognize screen or VDT-associated DED as a precision phenotype with an identifiable upstream environmental driver; connect sustained visual attention with reduced blink frequency, incomplete blinking, prolonged exposure, evaporation, and tear-film instability; distinguish screen-related symptoms from the actual tear-film mechanism; integrate VDT-specific randomized Omega-3 evidence without treating it as direct Keyora evidence; preserve environmental and blink correction as separate intervention tasks that cannot be replaced by nutritional exposure; reconstruct one- and two-softgel Keyora exposure; distinguish doubling declared exposure from doubling clinical effect; require phenotype matching before dose escalation; establish symptom-sign discordance as clinically useful information rather than automatic intervention failure; distinguish biological non-response from phenotype mismatch, endpoint mismatch, persistent external drivers, structural gland disease, or neurosensory contribution; operationalize the entire framework through Keyora [The Dry-Eye Phenotype Matching and Response Algorithm]; define the final decisions as Continue, Reclassify, or Escalate. Dry Eye Disease Is a Homeostasis Disorder The first principle of EP-13 is that the ocular surface functions as a coordinated biological system. A healthy tear-film environment depends upon: adequate aqueous availability; tear distribution; appropriate evaporation control; lipid-layer function; blinking; surface lubrication; optical continuity; epithelial protection; osmotic balance; sensory regulation. DED develops when this integrated state loses stability. The clinical diagnosis therefore identifies the presence of disease but does not automatically identify the dominant mechanism maintaining it. Keyora [The Tear-Film Homeostasis and Ocular-Surface Response Matrix] The Matrix organizes DED through: dominant etiological driver → tear-film homeostasis failure → functional tear consequence → ocular-surface stress → response object. Examples include: excessive evaporation → instability → reduced interblink tear continuity → hyperosmolar stress → TBUT / NIBUT, osmolarity, symptoms, or surface response. Or: reduced aqueous availability → limited tear reserve → instability and concentrated tear environment → surface stress → Schirmer-related and other aqueous-oriented endpoints. This architecture prevents different disease components from being treated as one generic dry-eye variable. Tear Stability Is Not Tear Quantity A central EP-13 distinction is: tear availability and: tear performance are different. A person may possess measurable tears while the film breaks up rapidly between blinks. Conversely, an aqueous-deficient phenotype can reduce the amount of fluid available to sustain surface hydration and tear-film performance. TBUT and NIBUT therefore address tear-film stability. Schirmer testing addresses a different physiological question related primarily to tear production or availability. One cannot substitute automatically for the other. Keyora [The Dry-Eye Evidence Object Map] The principal DED evidence objects include: Symptoms such as dryness, irritation, discomfort, visual fluctuation, and OSDI. Tear Stability including TBUT and NIBU